Given these evidences, it is clear that CD248+CAFs‐released IL‐8 enhances cisplatin chemoresistance in NSCLC via activation of NF‐κB and elevation of ABCB1 expression. Here, NFKB1 is linked to non-small cell lung carcinoma.